Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV™ (guanfacine) Extended Release Tablets, at a major psychiatric medical ...
HealthDay News — The Child Behavior Checklist-Attention Problem (CBCL-AP) scale and Conners Rating Scale-Revised (CRS-R) yield moderate sensitivity for diagnosing ...
September 3, 2009 — The US Food and Drug Administration has approved guanfacine extended-release tablets (Intuniv; Shire plc) for the once-daily treatment of attention-deficit hyperactivity disorder ...
HONOLULU - October 29, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV™ (guanfacine) Extended Release Tablets, at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback